OMH Osmetech

RNS Number:0810W
Osmetech PLC
19 December 2000


                      OSMETECH PLC

                   BOARD APPOINTMENTS

Osmetech  plc ("Osmetech or "the Company"),  the  world's
leading    electronic-nose   company    for    healthcare
applications,  today announces the appointment  of  James
White  as  Chief Executive Officer (CEO).  Mr  White  was
previously  Chief Operating Officer.  Dr Giap Wang  Chong
will resume a non-executive role with the Company, having
held the position of CEO since October 1999.

The Company also announces the board appointment of David
Grindrod,  previously  Head  of  Manufacturing,   as   an
executive director.

All of these changes will take place with effect from  22
December 2000.

There  are  no details to be disclosed pursuant  to  Rule
16.4(a) or 16.4(b) - 6.F.2(b) to (g) of the Listing Rules
in respect of David Grindrod.


Gordon Hall, Chairman, Osmetech plc said:

"The  Company is entering a new stage in its  development
and  remains  on target to file its first FDA submission,
for the detection of urinary tract infections, by the end
of January 2001.

"I  am  delighted that James White has agreed to take  up
the  role  of  CEO  and  am confident  that  he  will  be
successful in driving the business towards the commercial
goals of exploiting its platform technology.  The Company
remains clearly focused on the healthcare market and  we
will  continue to benefit from Wang Chong's  considerable
medical  expertise and continued involvement  as  a  non-
executive director."


Enquiries:

Osmetech plc             01270 216 444
James White

Bell Pottinger Financial 020 7353 9203
Rebecca Fox


Notes to Editors

* Osmetech  plc,  based in Crewe, designs,  develops  and
  manufactures   electronic   gas   and   odour   sensors
  (electronic  noses)  for use in the healthcare  sector.
  Osmetech's   multi-sensor  array  based   gas   sensing
  technology screens patients' samples and tests for  the
  presence of infection-causing bacteria. The Company  is
  currently  focusing its IP development on sensors  that
  can  detect  bacteria  associated  with  urinary  tract
  infections   (UTIs),  bacterial  vaginosis   (BV)   and
  pneumonia in ICU patients.

* Osmetech  announced at the start of this year that  the
  first  set  of  trials  for its UTI  product  had  been
  successful.  The  trials, carried out  at  St  Thomas',
  London,  and  the Brigham & Women's Hospital,  Harvard,
  USA,  enabled the company to obtain "proof of  concept"
  status for its technology. A submission to the Food and
  Drug  Administration (FDA) for approval of the  product
  capable  of satisfying the demands of the UTI point  of
  care  ("POC")  healthcare  market  sector  will  follow
  shortly.

* This year the Company has also undertaken a large proof
  of  concept  study  at  St  George's  Hospital  Medical
  School,  London,  to  confirm  the  potential  of   its
  Microbial Analyser in detecting BV. Back in October  it
  announced the results of this study and confirmed  that
  the  BV Analyser matches the diagnostic performance  of
  the  existing "gold standard" test. This Analyser  will
  also  be  moved  forward for FDA  clinical  trials  and
  subsequent FDA approval process.

* James White became COO of Osmetech in October 1999. His
  appointment  to  CEO  marks  the  next  stage  in   the
  Company's   development  as  it  passes   the   various
  milestones  towards the launch of a commercial  product
  and negotiations with potential licensing partners.

* David  Grindrod has worked at Osmetech since 1994.  For
  the  last  three  years he has managed the  development
  team   covering   hardware,   software,   sensors   and
  chemistry,   focusing  recently   on   providing   the
  technical  platform for the current FDA trials.   Prior
  to  joining Osmetech he had a number of roles at Oxford
  Instruments  Plc, including director of  a  subsidiary,
  Oxford Plasma Technology Ltd.

Osmetech (LSE:OMH)
Historical Stock Chart
From Jun 2024 to Jul 2024

Osmetech (LSE:OMH)
Historical Stock Chart
From Jul 2023 to Jul 2024